TRIM69 and neoplasm: Our current study validate TRIM69 as a mutually exclusive E3 ligase targeting EYA4 for polyubiquitylation and turnover, thereby perturbing its ability to deactivate β-catenin/ID2 pathway and suppress cell proliferation, self-renewal as well as tumor development of PDAC cells.